- Home
- LPA vs CADL Comparison
LPA vs CADL Comparison
Compare LPA & CADL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPA
- CADL
- Stock Information
- Founded
- LPA 2013
- CADL 1999
- Country
- LPA United States
- CADL United States
- Employees
- LPA N/A
- CADL N/A
- Industry
- LPA
- CADL Biotechnology: Pharmaceutical Preparations
- Sector
- LPA
- CADL Health Care
- Exchange
- LPA Nasdaq
- CADL Nasdaq
- Market Cap
- LPA 310.7M
- CADL 306.4M
- IPO Year
- LPA N/A
- CADL 2021
- Fundamental
- Price
- LPA $9.20
- CADL $8.06
- Analyst Decision
- LPA
- CADL Strong Buy
- Analyst Count
- LPA 0
- CADL 4
- Target Price
- LPA N/A
- CADL $21.00
- AVG Volume (30 Days)
- LPA 6.9K
- CADL 1.2M
- Earning Date
- LPA 03-25-2025
- CADL 03-13-2025
- Dividend Yield
- LPA N/A
- CADL N/A
- EPS Growth
- LPA N/A
- CADL N/A
- EPS
- LPA N/A
- CADL N/A
- Revenue
- LPA $44,311,428.00
- CADL N/A
- Revenue This Year
- LPA N/A
- CADL N/A
- Revenue Next Year
- LPA N/A
- CADL N/A
- P/E Ratio
- LPA N/A
- CADL N/A
- Revenue Growth
- LPA 22.46
- CADL N/A
- 52 Week Low
- LPA $6.00
- CADL $1.40
- 52 Week High
- LPA $525.00
- CADL $14.60
- Technical
- Relative Strength Index (RSI)
- LPA N/A
- CADL 45.77
- Support Level
- LPA N/A
- CADL $8.33
- Resistance Level
- LPA N/A
- CADL $9.08
- Average True Range (ATR)
- LPA 0.00
- CADL 0.59
- MACD
- LPA 0.00
- CADL -0.04
- Stochastic Oscillator
- LPA 0.00
- CADL 42.70
About LPA Logistic Properties of the Americas
Logistic Properties of the Americas is a fully-integrated, internally managed real estate company that develops, owns and manages a diversified portfolio of warehouse logistics assets in Central America and the South America. It focuses on modern Class A logistics real estate in high growth and high barrier-to-entry markets that are undersupplied and have low penetration rates.
About CADL Candel Therapeutics Inc.
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.